Close this search box.
Subscriber Log In

World Preview 2022 Report

After a 27-month rollercoaster ride, can we expect a return to normal?

Battered biotech is reviving after booming and busting in spectacular fashion. M&A is heating up as pharma companies face up to their patent cliff. And drug sales growth forecasts continue skyward.

Big pharma had a smoother ride– not just relative to biotech, but as a defensive stalwart amid huge macro-economic pressures. Then of course there’s the unpredictability of China and a hard-to-read FDA to consider.

The Evaluate Pharma World Preview 2022 explores the future of the pharma and biotech landscape, based on Evaluate consensus forecasts out to 2028.



Download Now


Related Blogs

Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.